Table 1. Demographic and disease characteristics by anti–HPV-16 VLP and anti–HPV-16 E6 and/or E7 antibody status.
| Characteristic | HPV-16 VLP seropositive* |
HPV-16 VLP seronegative |
Age-adjusted OR (95% CI) |
HPV-16 E6/E7 seropositive† |
HPV-16 E6/E7 seronegative |
Age-adjusted OR (95% CI) |
|---|---|---|---|---|---|---|
| n = 52 (%) | n = 104 (%) | n = 39 (%) | n = 117 (%) | |||
| Age (y) | ||||||
| ≤60 | 40 (77) | 54 (52) | 3.1 (1.5-6.5) | 32 (82) | 62 (53) | 4.1 (1.7-9.9) |
| >60 | 12 (23) | 50 (48) | 1.0 | 7 (18) | 55 (47) | 1.0 |
| Gender | ||||||
| Male | 32 (62) | 63 (61) | 0.9 (0.5-1.9) | 30 (77) | 65 (56) | 2.5 (1.1-5.7) |
| Female | 20 (38) | 41 (39) | 1.0 | 9 (23) | 52 (44) | 1.0 |
| Tobacco status | ||||||
| Never | 8 (15) | 34 (33) | 1.0 | 7 (18) | 35 (30) | 1.0 |
| Former | 15 (29) | 33 (32) | 2.2 (0.8-6.2) | 15 (38) | 33 (28) | 3.4 (1.1-10.2) |
| Current | 29 (56) | 37 (36) | 3.0 (1.2-7.6) | 17 (44) | 49 (42) | 1.5 (0.5-4.1) |
| Alcohol status | ||||||
| Never | 10 (19) | 33 (32) | 1.0 | 7 (18) | 36 (31) | 1.0 |
| Former | 13 (25) | 25 (24) | 1.7 (0.7-4.7) | 11 (28) | 27 (23) | 2.2 (0.7-6.5) |
| Current | 29 (56) | 46 (44) | 1.8 (0.8-4.3) | 21 (54) | 54 (46) | 1.6 (0.6-4.4) |
| Tumor site | ||||||
| Oropharynx | 26 (50) | 22 (21) | 3.4 (1.6-7.1) | 32 (82) | 16 (14) | 27.0 (10.0-72.7) |
| Oral cavity | 26 (50) | 82 (79) | 1.0 | 7 (18) | 101 (86) | 1.0 |
| Stage of disease | ||||||
| 0, I, II | 7 (13) | 38 (38) | 1.0 | 2 (5) | 44 (38) | 1.0 |
| III, IV | 45 (87) | 64 (62) | 3.8 (1.6-9.4) | 37 (95) | 72 (62) | 11.5 (2.6-50.7) |
| Tumor grade‡ | ||||||
| Well/moderate | 38 (75) | 81 (79) | 1.0 | 20 (54) | 99 (85) | 1.0 |
| Poor/undifferentiated | 13 (25) | 22 (21) | 1.0 (0.4-2.1) | 17 (46) | 18 (15) | 4.0 (1.7-9.3) |
| Nodal involvement | ||||||
| Yes | 37 (71) | 50 (49) | 2.4 (1.1-4.9) | 36 (92) | 50 (45) | 13.9 (4.0-47.8) |
| No | 15 (29) | 53 (51) | 1.0 | 3 (8) | 62 (55) | 1.0 |
| Histology | ||||||
| SCC | 48 (92) | 92 (88) | 1.7 (0.5-5.6) | 39 (100) | 101 (86) | 5.3 (0.7-41.7)§ |
| Non-SCC | 4 (8) | 12 (12) | 1.0 | 0 (0) | 16 (14) | 1.0 |
NOTE: Number of patients, percentages (%) based on available data.
Abbreviation: SCC, squamous cell carcinoma.
*
HPV-16 VLP defined as seropositive for HPV-16, compared with individuals HPV-16 VLP seronegative.
†
HPV-16 E6/E7 seropositive defined as seropositive for HPV-16 E6 and/or HPV-16 E7, compared with individuals seronegative for HPV-16 E6 and E7.
‡
Well/moderately differentiated versus poor/undifferentiated.
§
Logit estimator used to determine OR and CI.